Intel stock spikes after report of possible US government stake
Katherine Stueland, the Chief Executive Officer of GeneDx Holdings Corp. (NASDAQ:WGS), has sold shares worth approximately $4.18 million, according to a recent SEC filing. The transactions, executed on April 9, involved the sale of Class A common stock at prices ranging from $81.16 to $97.24 per share. The stock has shown remarkable momentum, gaining over 740% in the past year and currently trading at $92.62, with a market capitalization of $2.58 billion. Following these sales, Stueland now holds 1,720 shares directly. These transactions were conducted under a pre-established trading plan, as indicated in the filing. InvestingPro analysis suggests the stock is trading above its Fair Value, with analyst price targets ranging from $80 to $135. Get access to 10+ additional exclusive ProTips and comprehensive analysis through the InvestingPro Research Report.
In other recent news, GeneDx Holdings Corp reported robust financial performance for the fourth quarter of 2024, surpassing both earnings and revenue expectations. The company achieved earnings per share of $0.08, contrasting sharply with the projected loss of $0.48. Revenue reached $95.3 million, exceeding the anticipated $61.7 million, driven by a 101% year-over-year increase in exome and genome testing revenues. GeneDx also launched a new Ultra Rapid Whole Genome Sequencing product, enhancing their service offerings. The company expanded its sales team and integrated new operational strategies, further supporting its growth. Analysts have noted GeneDx's strategic focus on innovation and expansion into new indications like cerebral palsy and hearing loss. Looking ahead, GeneDx projects revenue guidance for 2025 between $350 million and $360 million, with an expected growth of at least 30% in exome and genome volume. The company aims to maintain a 65-67% adjusted gross margin, ensuring continued profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.